OVs engineered to enhance innate immune responses through the production of GM-CSF are currently the most advanced in clinical development19, 20, with the recent Food and Drug Administration approval of intralesional talimogene laherparepvec for the treatment of metastatic melanoma. This evidence concerns the gene CSF2 and metastatic melanoma.